News

Article

AAO 2023: Luminopia, first FDA-approved digital therapeutic for amblyopia

Author(s):

David Hutton,Sheryl Stevenson
Conferences|AAO

Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.

Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.

Related Videos
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Related Content
Winners of best poster presentation award at EnVision Summit 2025
March 6th 2025

Winners of best poster presentation award at EnVision Summit 2025

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Envision Summit 2025: Importance of comanagement in glaucoma treatment
February 15th 2025

Envision Summit 2025: Importance of comanagement in glaucoma treatment

Comparing micro-bypass implant + phaco vs phaco in POAG
December 23rd 2020

Comparing micro-bypass implant + phaco vs phaco in POAG

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function
October 22nd 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function

AAO 2024: New drug shows promise as first to protect vision in patients with dry AMD
October 21st 2024

AAO 2024: New drug shows promise as first to protect vision in patients with dry AMD

© 2025 MJH Life Sciences

All rights reserved.